Generic apixaban is expected to become available in the United States starting in 2026 [1]. This timeline is based on the expiration of key patents protecting Eliquis, the brand-name version of apixaban [1][2].
When do the main patents for Eliquis expire?
The primary patents for apixaban, including those covering its composition of matter and methods of use, are set to expire in 2026 and 2028 [1][3]. Specifically, the last of the key composition of matter patents is listed as expiring in 2028 [1].
Who manufactures Eliquis?
Eliquis is manufactured by Bristol Myers Squibb and Pfizer [4].
What is apixaban used for?
Apixaban is an anticoagulant medication used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation [5]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent recurrent DVT and PE [5].
What are the risks associated with apixaban?
The primary risk associated with apixaban, like other anticoagulants, is bleeding [5]. Patients are advised to seek immediate medical attention if they experience signs of serious bleeding, such as unusual bruising, nosebleeds, bleeding gums, blood in urine or stool, or prolonged bleeding from cuts [5].
How does apixaban compare to other anticoagulants?
Apixaban is a direct oral anticoagulant (DOAC) and is often compared to other DOACs like rivaroxaban (Xarelto) and dabigatran (Pradaxa), as well as older anticoagulants like warfarin [6]. DOACs like apixaban generally offer a more predictable anticoagulant effect than warfarin, often requiring less frequent monitoring [6].
Can biosimilars of apixaban be launched before patent expiry?
The availability of generic versions of apixaban is contingent upon patent expiration. Patent challenges or other legal mechanisms could potentially alter these timelines, but generally, generic entry is linked to patent expiry dates [1].
What is the expected price of generic apixaban?
While specific pricing for generic apixaban is not yet available, generic medications are typically offered at significantly lower prices than their brand-name counterparts [7]. This price reduction is a major driver for generic market entry and is anticipated once apixaban generics become available.
Sources:
[1] https://drugpatentwatch.com/brands/eliquis/patents
[2] https://drugpatentwatch.com/drug/apixaban
[3] https://drugpatentwatch.com/drug/eliquis
[4] https://www.eliquis.com/about-eliquis/manufacturer
[5] https://www.eliquis.com/hcp/about-eliquis/safety-information
[6] https://www.nejm.org/doi/full/10.1056/NEJMra1409940
[7] https://www.fda.gov/drugs/generic-drugs